Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs ...

Are you searching for effective medications to treat 'Amyotrophic Lateral Sclerosis (ALS)'? This comprehensive guide provides the latest information on medications-both generic and branded-that ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for ...

"FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatment" was originally created and published by Clinical Trials ...

The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...

PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, ...

Woolsey Pharmaceuticals has secured additional funds to continue advancing its ROCK inhibitor Bravyl (oral fasudil) for the ...

CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoimmune diseases. Its lead product is NeuroNata-R ...

“That’s when they were actually looking for the biomarkers so that they could develop the treatment,” said Sifford. The drug is the first of its kind for ALS. It targets the SOD-1 ...

Health regulators in Canada gave conditionally approval to Qalsody to treat adults whose ALS is due to mutations in the SOD1 gene.